Louise Moist, MD
Moist L. Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD. Ann Intern Med. 2019;171:JC43. doi: https://doi.org/10.7326/ACPJ201910150-043
Download citation file:
Published: Ann Intern Med. 2019;171(8):JC43.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use